Aviv Regev

In 2020, Regev became the Head and Executive Vice President of Genentech Research and Early Development, based in South San Francisco, and a member of the extended Corporate Executive Committee of Roche. Previously, she was a Core Institute Member (now on leave), Chair of the Faculty, Founding Director of the Klarman Cell Observatory and co-Director Cell Circuits Program at the Broad Institute of MIT and Harvard. She was also a professor in the Department of Biology at the Massachusetts Institute of Technology (now on leave), as well as an Investigator at the Howard Hughes Medical Institute. Regev's research includes work on gene expression (with Eran Segal and David Botstein), and the use of π-calculus to represent biochemical processes. Regev's team has been a leading pioneer of single-cell genomics experimental and computational methods. In 2014, she pitched the idea of the creation of Human Cell Atlas, a project to describe all cell types in the human body. Regev founded the Human Cell Atlas together with Sarah Teichmann along with collaborators all over the world.

Regev is a fellow of the International Society of Computational Biology (ISCB) (2017), a Helmholtz Fellow (2020), and a fellow of the American Association for Cancer Research (AACR) (2021). She is a member of the US National Academy of Sciences (NAS, elected 2019) and of the US National Academy of Medicine (NAM, elected 2020).

Aviv Regev (born July 11, 1971) is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member (on leave) at the Broad Institute of MIT and Harvard and professor (on leave) at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.